Article
Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy - 1 Dec 2024
Shoji Kensuke, Hikino Keiko, Saito Jumpei, Matsui Toshihiro, Utano Tomoyuki, Takebayashi Akira, Tomizawa Daisuke, Kato Motohiro, Matsumoto Kimikazu, Ishikawa Takashi, Kawai Toshinao, Nakamura Hidefumi, Miyairi Isao, Terao Chikashi, Mushiroda Taisei
Abstract excerpt
BACKGROUND: Voriconazole pharmacokinetics (PK) are known to be affected by genetic polymorphisms of drug-metabolizing enzymes such as CYP2C19; however, such information is limited for the pediatric population. The primary aim of this study is to establish a voriconazole PK model incorporating CYP2C19 phenotypes in Japanese children with malignancy or inborn errors of immunity. METHODS: CYP2C19 genotypes were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.